• Publications
  • Influence
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.
The increased binding of TEC-11 to tumor vasculature and to dividing as opposed to noncycling HUVECs in vitro suggests that endoglin is an endothelial cell proliferation-associated marker, which might have therapeutic value in the treatment of solid tumors in humans. Expand
Generation of a panel of related human scFv antibodies with high affinities for human CEA.
A panel of human anti-CEA scFvs has been generated with differing dissociation constants for antigen, which will allow the correlation between tumour targeting efficiency and binding affinity to be assessed directly and will be valuable in the optimisation of human antibodies for immunotherapy. Expand
Pathfinder selection: in situ isolation of novel antibodies.
This work demonstrates that an existing binding specificity can be used as a tool to select phage libraries in situ, obviating the need to purify or clone the target. Expand
Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome-inactivating protein alpha-sarcin from Aspergillus giganteus.
An immunotoxin was synthesized by the attachment of alpha-sarcin, the ribosome-inactivating protein derived from the mould Aspergillus giganteus, to a monoclonal mouse IgG2 antibody Fib75. TheExpand
Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.
The potential of mouse monoclonal antibodies for recognising different antigens associated with human small cell lung cancer (SCLC) to form active immunotoxins was assessed by an indirect in vitroExpand
An anti‐mucin immunotoxin BrE‐3‐ricin A‐chain is potently and selectively toxic to human small‐cell lung cancer
The findings suggest that anti‐mucin immunotoxins may have a therapeutic role to play in the treatment of SCLC. Expand
Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule
It is indicated that ricin A chain immunotoxins directed against N‐CAM on SCLC are unlikely to have sufficient activity to be useful therapeutic agents in the absence of potentiating agents such as monensin, which can interfere with the normal intracellular pathways of antigen routing. Expand
Monoclonal antibodies recognising the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immunotoxin cytotoxicity.
Mabs recognising antigens other than cluster 1 bound to NCI-H69 cells in amounts similar to those of the cluster 2 Mabs yet did not mediate potent cytotoxic effects in the indirect assay suggesting that the cluster 1 antigen may be internalised in a fashion favouring the delivery of ricin A chain to the cytosol. Expand
Enzyme immunoassays using bispecific diabodies.
The results illustrate the diagnostic potential of diabodies in enzyme immunoassays and demonstrate the use of recombinant bispecific antibody fragments against an enzyme. Expand
Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice.
HAH-cortisol represents the prototype of a new class of angiogenesis inhibitors for the treatment of cancer and other angiogenic diseases. Expand